Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.

Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B

Diabetes1 May 2002Cited by 205 (Europe PMC)

PMID11978641DOI10.2337/diabetes.51.5.1443PepBankPUB-11978641

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In neonatal Goto-Kakizaki rats, exendin‑4 increased pancreatic insulin content versus untreated rats.
In plain wordsIn rats with genetic diabetes risk, neonatal exendin‑4 increased pancreatic insulin content versus untreated rats.
Peptide
Exenatide (exendin-4)
Outcome
IncreasePancreatic insulin content
Study
ratn: not reported in source
Goto-Kakizaki rats
Comparator
untreated GK rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 microg/kg/day · injection · day 2 to day 6 after birthAs given in this study (rat).
Source sentences
Summary
Under these conditions, on day 7 both treatments enhanced pancreatic insulin content and total beta-cell mass by stimulating beta-cell neogenesis and regeneration.
1 context sentence(design, population, supporting numbers)
Summary · context
GK rats were treated with daily injections of glucagon-like peptide-1 (400 microg x kg(-1) x day(-1)) or Ex-4 (3 microg x kg(-1) x day(-1)) from day 2 to day 6 after birth and were evaluated against Wistar and untreated GK rats.
Report a problemFND-1197864101
02AnimalAnimal study (in vivo)Efficacy outcome
In neonatal Goto-Kakizaki rats, exendin‑4 increased total beta-cell mass versus untreated rats.
In plain wordsIn rats with genetic diabetes risk, neonatal exendin‑4 increased insulin-producing cell mass versus untreated rats.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseTotal beta-cell mass
Study
ratn: not reported in source
Goto-Kakizaki rats
Comparator
untreated GK rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 microg/kg/day · injection · day 2 to day 6 after birthAs given in this study (rat).
Source sentences
Summary
Under these conditions, on day 7 both treatments enhanced pancreatic insulin content and total beta-cell mass by stimulating beta-cell neogenesis and regeneration.
1 context sentence(design, population, supporting numbers)
Summary · context
GK rats were treated with daily injections of glucagon-like peptide-1 (400 microg x kg(-1) x day(-1)) or Ex-4 (3 microg x kg(-1) x day(-1)) from day 2 to day 6 after birth and were evaluated against Wistar and untreated GK rats.
Report a problemFND-1197864102
03AnimalAnimal study (in vivo)Mechanism
In neonatal Goto-Kakizaki rats, exendin‑4 stimulated beta-cell neogenesis versus untreated GK rats.
In plain wordsIn rats, neonatal exendin‑4 stimulated formation of new insulin-producing cells versus untreated GK rats.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBeta-cell neogenesis
Study
ratn: not reported in source
Goto-Kakizaki rats
Comparator
untreated GK rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 microg/kg/day · injection · day 2 to day 6 after birthAs given in this study (rat).
Source sentences
Summary
Under these conditions, on day 7 both treatments enhanced pancreatic insulin content and total beta-cell mass by stimulating beta-cell neogenesis and regeneration.
1 context sentence(design, population, supporting numbers)
Summary · context
GK rats were treated with daily injections of glucagon-like peptide-1 (400 microg x kg(-1) x day(-1)) or Ex-4 (3 microg x kg(-1) x day(-1)) from day 2 to day 6 after birth and were evaluated against Wistar and untreated GK rats.
Report a problemFND-1197864103
04AnimalAnimal study (in vivo)Efficacy outcome
In Goto-Kakizaki rats, neonatal exendin‑4 had lasting favorable effects on adult beta-cell mass versus untreated GK rats.
In plain wordsIn rats, neonatal exendin‑4 had lasting favorable effects on adult insulin-producing cell mass versus untreated GK rats.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseAdult beta-cell mass
Study
ratn: not reported in source
Goto-Kakizaki rats
Comparator
untreated GK rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 microg/kg/day · injection · day 2 to day 6 after birthAs given in this study (rat).
Source sentences
Summary
Follow-up of biological characteristics from day 7 to adult age (2 months) showed that such a GLP-1 or Ex-4 treatment exerted long-term favorable influences on beta-cell mass and glycemic control at adult age.
1 context sentence(design, population, supporting numbers)
Summary · context
GK rats were treated with daily injections of glucagon-like peptide-1 (400 microg x kg(-1) x day(-1)) or Ex-4 (3 microg x kg(-1) x day(-1)) from day 2 to day 6 after birth and were evaluated against Wistar and untreated GK rats.
Report a problemFND-1197864104
05AnimalAnimal study (in vivo)Efficacy outcome
In adult Goto-Kakizaki rats, neonatal exendin‑4 reduced basal plasma glucose versus untreated rats.
In plain wordsIn rats, neonatal exendin‑4 lowered adult basal plasma glucose versus untreated GK rats.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAdult basal plasma glucose
Study
ratn: not reported in source
Goto-Kakizaki rats
Comparator
untreated GK rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 microg/kg/day · injection · day 2 to day 6 after birthAs given in this study (rat).
Source sentences
Summary
As compared to untreated GK rats, 2-month-old treated rats exhibited significantly decreased basal plasma glucose.
1 context sentence(design, population, supporting numbers)
Summary · context
GK rats were treated with daily injections of glucagon-like peptide-1 (400 microg x kg(-1) x day(-1)) or Ex-4 (3 microg x kg(-1) x day(-1)) from day 2 to day 6 after birth and were evaluated against Wistar and untreated GK rats.
Report a problemFND-1197864105
06AnimalAnimal study (in vivo)Efficacy outcome
In adult Goto-Kakizaki rats, neonatal exendin‑4 slightly improved insulin secretion after intravenous glucose versus untreated rats.
In plain wordsIn rats with genetic diabetes risk, neonatal exendin‑4 slightly improved adult insulin release after glucose versus untreated rats.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseGlucose-stimulated insulin secretion in vivo
Study
ratn: not reported in source
Goto-Kakizaki rats
Comparator
untreated GK rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 microg/kg/day · injection · day 2 to day 6 after birthAs given in this study (rat).
Source sentences
Summary
Their glucose-stimulated insulin secretion, in vivo after intravenous glucose load or in vitro using isolated perfused pancreas, was slightly improved.
2 context sentences(design, population, supporting numbers)
Summary · context
As compared to untreated GK rats, 2-month-old treated rats exhibited significantly decreased basal plasma glucose.
Summary · context
GK rats were treated with daily injections of glucagon-like peptide-1 (400 microg x kg(-1) x day(-1)) or Ex-4 (3 microg x kg(-1) x day(-1)) from day 2 to day 6 after birth and were evaluated against Wistar and untreated GK rats.
Report a problemFND-1197864106
07AnimalAnimal study (in vivo)Efficacy outcome
In Goto-Kakizaki rats, neonatal exendin‑4 increased adult plasma glucose disappearance rate versus untreated rats.
In plain wordsIn rats with genetic diabetes risk, neonatal exendin‑4 increased adult glucose clearance versus untreated rats.
Peptide
Exenatide (exendin-4)
Outcome
IncreasePlasma glucose disappearance rate
Study
ratn: not reported in source
Goto-Kakizaki rats
Comparator
untreated GK rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 microg/kg/day · injection · day 2 to day 6 after birthAs given in this study (rat).
Source sentences
Summary
This contributed at least partly to improve the in vivo plasma glucose disappearance rate, which was found to be increased in both treated GK groups compared to the untreated GK group.
1 context sentence(design, population, supporting numbers)
Summary · context
GK rats were treated with daily injections of glucagon-like peptide-1 (400 microg x kg(-1) x day(-1)) or Ex-4 (3 microg x kg(-1) x day(-1)) from day 2 to day 6 after birth and were evaluated against Wistar and untreated GK rats.
Report a problemFND-1197864108
08AnimalAnimal study (in vivo)Mechanism
In neonatal Goto-Kakizaki rats, exendin‑4 stimulated beta-cell regeneration versus untreated GK rats.
In plain wordsIn rats, neonatal exendin‑4 stimulated regeneration of insulin-producing cells versus untreated GK rats.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBeta-cell regeneration
Study
ratn: not reported in source
Goto-Kakizaki rats
Comparator
untreated GK rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 microg/kg/day · injection · day 2 to day 6 after birthAs given in this study (rat).
Source sentences
Summary
Under these conditions, on day 7 both treatments enhanced pancreatic insulin content and total beta-cell mass by stimulating beta-cell neogenesis and regeneration.
1 context sentence(design, population, supporting numbers)
Summary · context
GK rats were treated with daily injections of glucagon-like peptide-1 (400 microg x kg(-1) x day(-1)) or Ex-4 (3 microg x kg(-1) x day(-1)) from day 2 to day 6 after birth and were evaluated against Wistar and untreated GK rats.
Report a problemFND-1197864109
09LabEx vivo tissueEfficacy outcome
In isolated perfused pancreases from Goto-Kakizaki rats, prior neonatal exendin‑4 slightly improved glucose-stimulated insulin secretion versus untreated rats.
In plain wordsIn lab tests of rat pancreases, prior neonatal exendin‑4 slightly improved glucose-stimulated insulin release versus untreated rats.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseGlucose-stimulated insulin secretion in perfused pancreas
Study
ratn: not reported in source
isolated perfused pancreas from treated GK rats
Comparator
untreated GK rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 microg/kg/day · injection · day 2 to day 6 after birthAs given in this study (rat).
Source sentences
Summary
Their glucose-stimulated insulin secretion, in vivo after intravenous glucose load or in vitro using isolated perfused pancreas, was slightly improved.
2 context sentences(design, population, supporting numbers)
Summary · context
As compared to untreated GK rats, 2-month-old treated rats exhibited significantly decreased basal plasma glucose.
Summary · context
GK rats were treated with daily injections of glucagon-like peptide-1 (400 microg x kg(-1) x day(-1)) or Ex-4 (3 microg x kg(-1) x day(-1)) from day 2 to day 6 after birth and were evaluated against Wistar and untreated GK rats.
Report a problemFND-1197864107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.